Kamalakar Surineni, MD, MPH,FAPA

Professional Background

Dr. Kamalakar Surineni is a board-certified psychiatrist (ABPN) and Clinical Assistant Professor. He serves as the attending supervisor for the University of Kansas Geriatric Psychiatry Services and chairs the Psychiatry Section at Ascension Via Christi hospitals. Dr. Surineni provides both inpatient and outpatient mental health care for older Kansans, including outpatient services to the VC-HOPE PACE® program.

Dr. Surineni is deeply committed to medical education, actively mentoring psychiatry residents and medical students while advocating for expanded mental health outreach in underserved communities. Dr Surineni is well published and serves as an investigator in multiple clinical trials focused on dementia and other psychiatric/medical conditions.

He holds multiple critical academic roles within the American Psychiatric Association (APA), including member of the Maintenance of Certification Committee (ABPN), Access to Care Committee, Nominations Committee, and Health Disparities Committee. He also serves as the President-Elect of the Kansas Psychiatric Society.

As a member of the Kansas Drug Utilization Review Board (KDHE), and the Governor’s Aging Subcommittee (KDADS), Dr. Surineni contributes his expertise to advancing healthcare policy and improving services for older Kansans.

• MBBS, Medicine, Kakatiya Medical College, India
• MPH, Public Health (Epidemiology, Biostatistics), Missouri State University, Springfield, MO
• Residency, Psychiatry , University of Kansas Medical Center, Wichita, Kansas

• Kamalakar Surineni, Kansas State Board of Healing Arts

• American Psychiatric Association, Nominations committee, Member, 2025 - Present
• American Psychiatric Association, Early Career Psychiatrist Representative , Member, 2024 - Present
• American Psychiatric Association, Rules Committee , Member, 2024 - Present
• American Psychiatric Association, APA- Federal Advocacy Representative of KPS, 2023 - 2023
• Indo-American Psychiatric Association, Member, 2022 - Present
• American Medical Association , Member, 2017 - Present
• American Psychiatric Association, Member, 2017 - Present

• A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-Finding Study with an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease (BAN2401-G000-201): Closed for active enrollment; Dr Surineni is helping with followup clinical trial appointments. , Eisai Inc
• Kansas University Alzheimer's Disease Center Registry, Dr Surineni is helping with screening for eligible patients, in person clinical trial patient visits, Physical Examinations and laboratory interpretation and management. , Kansas University Alzheimer's Disease Center
• Metformin in Alzheimer’s dementia Prevention (MAP) Study. Dr Surineni is helping with in person clinical trial patient visits, Physical Examinations and laboratory interpretation and management. , National Institutes of Health (NIH) through the National Institute on Aging (NIA)
• Ranolazine in ALS: safety, and effect on cramps, function and quality of life., University of Kansas

• Martin, Phillip., K., Surineni, Kamalakar, Schroeder, Ryan., W., Hilsabeck, Robin., C., Ayers, Gayle., Y.. 2024. Diagnostic Interviewing and Cognitive Screening, 13-28. https://doi.org/10.1093/med/9780197690024.003.0003
• Li, Susan, Surineni, Kamalakar. 2025. Falls in Hospitalized Patients and Preventive Strategies: A Narrative Review. The American Journal of Geriatric Psychiatry: Open Science, Education, and Practice, 5, 1-9. https://doi.org/10.1016/j.osep.2024.10.004
• Pirtle, Jimmie., L., Hickman, Melissa., D., Boinpelly, Varun., C., Surineni, Kamalakar, Thakur, Hemant., K., Grasing, Kenneth., W.. 2019. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study. Pharmacology Biochemistry and Behavior, 180, 52-59. https://doi.org/10.1016/j.pbb.2019.02.010
• Li, Susan, Surineni, Kamalakar, Prabhakaran, Nishant. 2025. Cyber-Attacks on Hospital Systems: A Narrative Review. The American Journal of Geriatric Psychiatry: Open Science, Education, and Practice. https://doi.org/10.1016/j.osep.2025.03.002
• Surineni, Kamalakar, Le, Vy, McKaughan, Kevin, Fotion, Namie. 2025. Use of Paliperidone Long-Acting Injections in Huntington's Disease. Journal of Clinical Psychopharmacology, 45 (3), 293-295. https://doi.org/10.1097/jcp.0000000000001989
• Sharma, Ram, Oni, OA, Gu, Kamal, Sharma, M, Singh, V, Parashara, D, Surineni, K, B., Dawn, Chen, G, Ambrose, JA, Barua, R. 2017. Normalization of Testosterone Levels After Testosterone Replacement Therapy Is Associated With Decreased Incidence of Atrial Fibrillation. https://www.ahajournals.org/doi/10.1161/JAHA.116.004880
• Le, Vy, Wollard, Kylee , Kamalakar. 2023. Post-ictal and Inter-ictal Persistent Delirium in A 69-year-old With Resected Bifrontal Olfactory Groove Skull Base Meningioma. Kansas Medical Journal
• Surineni, Kamalakar, Le, Vy, Jones, Danielle. 2024. A Case of Oral-Buccal-Lingual Dyskinesia and Neuropsychiatric Symptoms After Prolonged Levetiracetam Exposure. Cureus. https://doi.org/10.7759/cureus.62692
• Surineni, Kamalakar, Muhammad, Afzal, Barua, Rajath, Parashara, Deepak. 2016. Epinephrine-Induced Takotsubo Cardiomyopathy,. https://pmc.ncbi.nlm.nih.gov/articles/PMC6373712/
• Surineni, Kamalakar, Wells, Emilee, Schrader, Nolan, Costa, Gilmar, Ziegler, Maggie. 2024. Valproate-Induced Thrombocytopenia: A Case Report. Cureus. https://doi.org/10.7759/cureus.65670